Showing results (1751-1760 of 1,762) with videos related to

Sort By:
Pageof 177
Clinical Lung Cancer|October 25, 2023
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)Jia-Tao Zhang, Song Dong, Wei-Quan Gu, et al.
Nature Communications|April 3, 2026
Probing ultrafast heating and ionization dynamics in solid density plasmas with time-resolved resonant X-ray absorption and emissionLingen Huang, Mikhail Mishchenko, Michal Šmíd, et al.
Scientific Reports|June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Nature Communications|August 31, 2018
Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogrammingDavid Olagnier, Aske M Brandtoft, Camilla Gunderstofte, et al.
Nature Communications|August 17, 2017
Genome re-sequencing reveals the history of apple and supports a two-stage model for fruit enlargementNaibin Duan, Yang Bai, Honghe Sun, et al.
Hepatology (Baltimore, Md.)|February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer|June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter StudyDa-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Liver Cancer|January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
Liver Cancer|July 11, 2026
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective StudyLin Ye, Guo-Xing Liu, Da-Long Yang, et al.
Communications Medicine|March 13, 2026
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)Da-Long Yang, Chuang Qin, Ning Peng, et al.
Pageof 177